New drug may shield kidneys in fatty liver cirrhosis patients
NCT ID NCT07585526
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests whether the drug finerenone can prevent chronic kidney disease in 160 adults with fatty liver disease (MASLD), cirrhosis, and fluid in the belly (ascites). Participants will receive either finerenone or spironolactone alongside standard care. The main goal is to see if finerenone reduces the number of people who develop kidney problems over 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.